Pancreatic Cancer Research

ResearcherUniversity College DublinActive in the last 2 years

Grainne Mary O'Kane

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-8690-403X; OpenAlex author ID A5017021482, A5122783029, A5122812254. Sources: OpenAlex.

Their work

Papers
59 (first author 4, last author 8)
Trials
0
Grants
0
Labs led
1
Collaborators
173
Papers, trials and grants by year

2018: 3 papers · 2019: 1 paper · 2020: 7 papers · 2021: 12 papers · 2022: 7 papers · 2023: 6 papers · 2024: 5 papers · 2025: 9 papers · 2026: 9 papers

Papers 50 of 59

  1. Precision Medicine in Pancreatic Cancer: Targeting KRAS and Beyond. Co-author DOI 10.1007/s11523-026-01236-x↗
  2. Neoadjuvant quadruplet chemotherapy PAXG for pancreatic cancer. Last author DOI 10.1016/s0140-6736(25)01864-1↗
  3. Development and Validation of a Computational Histology Artificial Intelligence-Powered Predictive Biomarker for Selection of Chemotherapy in Advanced Pancreat… Co-author DOI 10.1200/jco-25-02199↗
  4. Development of a Core Outcome Set for Pancreatic Cancer Rehabilitation – A Study Protocol Co-author DOI 10.12688/hrbopenres.14558.1↗
  5. Examination of DNA methylation patterns in pancreatic ductal adenocarcinoma Co-author DOI 10.21203/rs.3.rs-10421877/v1↗
  6. Multi-modal digital twin model outperforms conventional biomarker stratification in pancreatic cancer. Co-author DOI 10.3389/frai.2026.1873681↗
  7. Transcriptomic, Genomic, and Clinical Characterization of Morphological Classes in Localized and Metastatic Pancreatic Cancer Co-author DOI 10.64898/2026.04.07.717011↗
  8. Extra-lineage tissue programs define the transcription states of human pancreatic cancer Co-author DOI 10.64898/2026.04.29.721655↗
  9. Multimodal Machine Learning for Predicting Outcomes in the PASS-01 Trial of Systemic Therapy for Metastatic Pancreatic Cancer Co-author DOI 10.64898/2026.08.24.26360900↗
  10. Minimally invasive determination of pancreatic ductal adenocarcinoma (PDAC) subtype by means of circulating cell-free RNA. Co-author DOI 10.1002/1878-0261.13747↗
  11. GATA6 immunohistochemistry and prognosis after surgical resection of pancreatic adenocarcinoma: results from the ESPAC-4 trial. Co-author DOI 10.1016/j.esmogo.2025.100138↗
  12. Multi-omics whole-genome characterization of the copy number landscape of metastatic pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.isci.2025.113176↗
  13. Whole genome and transcriptome profiling in advanced pancreatic cancer patients on the COMPASS trial. Last author DOI 10.1038/s41467-025-60808-z↗
  14. The tandem duplicator phenotype may be a novel targetable subgroup in pancreatic cancer. Co-author DOI 10.1038/s41698-025-00888-8↗
  15. Integrated spatial proteomics of human PDAC uncovers an expanded tumour-immune-stroma spectrum with genomic associations Co-author DOI 10.1101/2025.08.15.670565↗
  16. The subclonal footprint of pervasive early dissemination in pancreatic cancer Co-author DOI 10.1101/2025.11.27.690823↗
  17. PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives for Previously Untreated Metastatic Panc… First author DOI 10.1200/jco-25-00436↗
  18. Erratum: PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives for Previously Untreated Metast… First author DOI 10.1200/jco-25-02195↗
  19. The neoadjuvant approach in resectable pancreatic ductal adenocarcinoma: lessons learned. Last author DOI 10.1016/s2468-1253(23)00451-x↗
  20. Cytidine deaminases APOBEC3C and APOBEC3D promote DNA replication stress resistance in pancreatic cancer cells. Co-author DOI 10.1038/s43018-024-00742-z↗
  21. Chemotherapy switch for localized pancreatic cancer: a systematic review and meta-analysis. Co-author DOI 10.1093/bjs/znae244↗
  22. nSMase2-mediated exosome secretion shapes the tumor microenvironment to immunologically support pancreatic cancer Co-author DOI 10.1101/2024.09.23.614610↗
  23. Targeting KRAS mutations in pancreatic cancer: opportunities for future strategies. Last author DOI 10.3389/fmed.2024.1369136↗
  24. Systemic inflammatory prognostic scores in advanced pancreatic adenocarcinoma. Last author DOI 10.1038/s41416-023-02214-0↗
  25. Molecular characterisation of pancreatic ductal adenocarcinoma with NTRK fusions and review of the literature. Last author DOI 10.1136/jclinpath-2021-207781↗
  26. hENT1 as a Predictive Biomarker in PDAC-Response. Last author DOI 10.1158/1078-0432.ccr-23-0887↗
  27. Spectrum of Response to Platinum and PARP Inhibitors in Germline BRCA-Associated Pancreatic Cancer in the Clinical and Preclinical Setting. Co-author DOI 10.1158/2159-8290.cd-22-0412↗
  28. Determinants of gemcitabine response in pancreatic cancer: are we there? First author DOI 10.21037/jgo-2023-04↗
  29. Clinically impactful metabolic subtypes of pancreatic ductal adenocarcinoma (PDAC). Co-author DOI 10.3389/fgene.2023.1282824↗
  30. Correlation of transcriptional subtypes with a validated CT radiomics score in resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00330-022-09057-y↗
  31. Integrative analysis of KRAS wildtype metastatic pancreatic ductal adenocarcinoma reveals mutation and expression-based similarities to cholangiocarcinoma. Co-author DOI 10.1038/s41467-022-33718-7↗
  32. Correction: GATA6 Expression Distinguishes Classical and Basal-like Subtypes in Advanced Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-22-1272↗
  33. hENT1 Expression Predicts Response to Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1158/1078-0432.ccr-22-2576↗
  34. Moving the Needle on Precision Medicine in Pancreatic Cancer. Co-author DOI 10.1200/jco.21.02514↗
  35. Intra-Tumoral CD8+ T-Cell Infiltration and PD-L1 Positivity in Homologous Recombination Deficient Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3389/fonc.2022.860767↗
  36. Is Biannual Surveillance for Pancreatic Cancer Sufficient in Individuals With Genetic Syndromes or Familial Pancreatic Cancer? Co-author DOI 10.6004/jnccn.2021.7107↗
  37. Prognostic value of early changes in CT-measured body composition in patients receiving chemotherapy for unresectable pancreatic cancer. Co-author DOI 10.1007/s00330-021-07899-6↗
  38. Spatially confined sub-tumor microenvironments in pancreatic cancer. Co-author DOI 10.1016/j.cell.2021.09.022↗
  39. A Risk Score Model for Locoregional Recurrence Following Upfront Surgery for Pancreatic Adenocarcinoma: Implications for Adjuvant Therapy. Co-author DOI 10.1016/j.clon.2021.03.007↗
  40. Genomic sequencing to inform therapy in advanced pancreatic cancer: A systematic review and meta-analysis of prospective studies. Co-author DOI 10.1016/j.ctrv.2021.102310↗
  41. The value of GATA6 immunohistochemistry and computer-assisted diagnosis to predict clinical outcome in advanced pancreatic cancer. Co-author DOI 10.1038/s41598-021-94544-3↗
  42. Genomic Features and Classification of Homologous Recombination Deficient Pancreatic Ductal Adenocarcinoma. First author DOI 10.1053/j.gastro.2021.01.220↗
  43. Simulated dose painting of hypoxic sub-volumes in pancreatic cancer stereotactic body radiotherapy. Co-author DOI 10.1088/1361-6560/ac215c↗
  44. Clinical and genomic characterisation of mismatch repair deficient pancreatic adenocarcinoma. Co-author DOI 10.1136/gutjnl-2020-320730↗
  45. Delving into Early-onset Pancreatic Ductal Adenocarcinoma: How Does Age Fit In? Co-author DOI 10.1158/1078-0432.ccr-20-1042↗
  46. Subtype-Discordant Pancreatic Ductal Adenocarcinoma Tumors Show Intermediate Clinical and Molecular Characteristics. Co-author DOI 10.1158/1078-0432.ccr-20-2831↗
  47. Validation of Prognostic Radiomic Features From Resectable Pancreatic Ductal Adenocarcinoma in Patients With Advanced Disease Undergoing Chemotherapy. Co-author DOI 10.1177/0846537120968782↗
  48. Advances in the management of pancreatic ductal adenocarcinoma. Co-author DOI 10.1503/cmaj.201450↗
  49. Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution. Co-author DOI 10.1038/s41588-019-0566-9↗
  50. Author Correction: Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution. Co-author DOI 10.1038/s41588-020-0588-3↗

Closest collaborators

The 25 strongest of 173 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Steve Gallinger · 47 shared papers, 2018–2026 · strength 6.27
  2. Jennifer Jane Knox · 41 shared papers, 2018–2026 · strength 5.38
  3. Faiyaz Notta · 36 shared papers, 2018–2026 · strength 4.92
  4. Robert C. Grant · 32 shared papers, 2018–2026 · strength 4.53
  5. Sandra Elisabeth Fischer · 23 shared papers, 2018–2026 · strength 2.68
  6. Erica S. Tsang · 12 shared papers, 2021–2026 · strength 1.99
  7. George Zogopoulos · 18 shared papers, 2019–2025 · strength 1.97
  8. Barbara T. Grünwald · 13 shared papers, 2020–2026 · strength 1.83
  9. Daniel John Renouf · 13 shared papers, 2020–2025 · strength 1.54
  10. Yifan Wang · 12 shared papers, 2020–2025 · strength 1.32
  11. Michelle Chan‐Seng‐Yue · 9 shared papers, 2019–2026 · strength 1.26
  12. David F. Schaeffer · 11 shared papers, 2020–2025 · strength 1.21
  13. Ayelet Borgida · 11 shared papers, 2019–2026 · strength 1.21
  14. Eugenia Flores Figueroa · 7 shared papers, 2020–2026 · strength 1.19
  15. Joanna M. Karasinska · 10 shared papers, 2020–2025 · strength 1.12
  16. Spring Holter · 9 shared papers, 2018–2026 · strength 1.11
  17. David Arthur Tuveson · 7 shared papers, 2020–2026 · strength 1.03
  18. James Thomas Topham · 9 shared papers, 2020–2025 · strength 0.96
  19. Oliver F. Bathe · 7 shared papers, 2021–2025 · strength 0.92
  20. Raymond Jang · 5 shared papers, 2021–2025 · strength 0.75
  21. Eileen Mary O'Reilly · 4 shared papers, 2024–2026 · strength 0.71
  22. Bas Groot Koerkamp · 2 shared papers, 2024–2026 · strength 0.68
  23. Christoph Benedikt Westphalen · 2 shared papers, 2024–2026 · strength 0.66
  24. Kai Duan · 4 shared papers, 2021–2025 · strength 0.65
  25. Rachel Anne Goodwin · 5 shared papers, 2021–2025 · strength 0.64

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.